{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:32:56Z","timestamp":1788715976737,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000031","name":"Institute of Human Development Child and Youth Health","doi-asserted-by":"publisher","award":["PJT-159782"],"award-info":[{"award-number":["PJT-159782"]}],"id":[{"id":"10.13039\/501100000031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104348","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:34:26Z","timestamp":1780443266000},"page":"104348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A unified physiologically based pharmacokinetic model for low-to-high oral, subcutaneous, and intravenous dose of methotrexate in humans"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-4701","authenticated-orcid":false,"given":"Min-Soo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0906-7084","authenticated-orcid":false,"given":"Shirley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Theoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Autmizguine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-3075","authenticated-orcid":false,"given":"Shinya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1653","authenticated-orcid":false,"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104348_bib0001","unstructured":"Datapharm. Summary of product characteristics (SMPc) methotrexate. 2025."},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0002","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/cpt.3329","article-title":"Comprehensive evaluation of OATP- and BCRP-mediated drug\u2013Drug interactions of methotrexate using physiologically-based pharmacokinetic modeling","volume":"116","author":"Hwang","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2014How does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.xphs.2026.104348_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-024-04653-9","article-title":"Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children\u2019s Research Hospital","author":"Gaietto","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2026.104348_bib0005","unstructured":"Datapharm. Summary of product characteristics of methotrexate 2.5 mg tablets."},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0006","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xphs.2026.104348_bib0007","unstructured":"International Council for Harmonisation. ICH haromised guideline - biopharmaceutics classification system-based biowaivers M9. 2019."},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.xphs.2026.104348_bib0009","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jps.2600790907","article-title":"Effect of Aspirin and sulindac on methotrexate clearance","volume":"79","author":"Furst","year":"1990","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/rheumatology\/34.5.421","article-title":"Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients","volume":"34","author":"Combe","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jps.2600780219","article-title":"Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients","volume":"78","author":"Herman","year":"1989","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0012","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2026.104348_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118907","article-title":"The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis","volume":"268","author":"Gao","year":"2021","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0014","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/jpet.300.3.918","article-title":"Human organic anion transporters and human organic cation transporters mediate renal antiviral transport","volume":"300","author":"Takeda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/toxsci\/kfu162","article-title":"SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients","volume":"142","author":"Lima","year":"2014","journal-title":"Toxicol Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0016","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1124\/jpet.107.121491","article-title":"Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by Human kidney slices","volume":"322","author":"Nozaki","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1996.04038.x","article-title":"Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response","volume":"42","author":"Haagsma","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0018","first-page":"845","article-title":"Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis","volume":"24","author":"H\u00fcbner","year":"1997","journal-title":"J Rheumatol"},{"issue":"6120","key":"10.1016\/j.xphs.2026.104348_bib0019","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bmj.1.6120.1097","article-title":"Prolongation and enhancement of serum methotrexate concentrations by probenecid","volume":"1","author":"Aherne","year":"1978","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/psp4.12619","article-title":"PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction","volume":"10","author":"Bolleddula","year":"2021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0021","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/clpt.1990.69","article-title":"Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis","volume":"47","author":"Stewart","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104348_bib0022","article-title":"Evaluation of BCRP-related DDIs between methotrexate and cyclosporin A using physiologically based pharmacokinetic modelling","author":"Schaller","year":"2024","journal-title":"Drugs R&D"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104348_bib0024","unstructured":"US FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers. Available at: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table4-2. Accessed September 19, 2000."},{"issue":"10","key":"10.1016\/j.xphs.2026.104348_bib0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/dmd.113.053082","article-title":"Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship","volume":"41","author":"Fu","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2026.104348_bib0026","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jps.2600600803","article-title":"Methotrexate Pharmacokinetics","volume":"60","author":"Bischoff","year":"1971","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104348_bib0027","series-title":"ASCPT Annual Meeting2018","article-title":"Evaluation of clinical DDI potential of methotrexate using PBPK modeling","author":"Ke","year":"2018"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","article-title":"PK-Sim\u00ae: a physiologically based pharmacokinetic \u2018whole-body\u2019 model","volume":"1","author":"Willmann","year":"2003","journal-title":"Biosilico"},{"key":"10.1016\/j.xphs.2026.104348_bib0029","series-title":"R: A Language and Environment for Statistical Computing","year":"2023"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0030","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0031","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0032","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","article-title":"Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption","volume":"127","author":"Qiu","year":"2006","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0034","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.1780330620","article-title":"Biliary elimination of low-dose methotrexate in humans","volume":"33","author":"Nuernberg","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xphs.2026.104348_bib0035","series-title":"OSP-PBPK-Model-library Version 11.2.1","year":"2021"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0036","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1023\/A:1016192413308","article-title":"Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?","volume":"19","author":"Tang","year":"2002","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.xphs.2026.104348_bib0037","first-page":"2077","article-title":"Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate","volume":"29","author":"Carmichael","year":"2002","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.xphs.2026.104348_bib0038","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1200\/JCO.1988.6.12.1882","article-title":"Pharmacokinetics of subcutaneous methotrexate","volume":"6","author":"Balis","year":"1988","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0039","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00434358","article-title":"The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy","volume":"14","author":"Stewart","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/bjc.1973.190","article-title":"Methotrexate in liver and bile after intravenous dosage in man","volume":"28","author":"Creaven","year":"1973","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0041","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0959-8049(01)00386-0","article-title":"Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours","volume":"38","author":"Louwerens","year":"2002","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0042","first-page":"405","article-title":"Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma 1, 2","volume":"63","author":"Wang","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0043","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/clpt.1983.37","article-title":"Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion","volume":"33","author":"Evans","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2026.104348_bib0044","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jps.2600800804","article-title":"Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children","volume":"80","author":"Chatelut","year":"1991","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2026.104348_bib0045","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1345\/aph.1E044","article-title":"Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients","volume":"38","author":"Hartmann","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.xphs.2026.104348_bib0046","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780350708","article-title":"The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers","volume":"35","author":"Kozloski","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0047","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/jpet.119.257089","article-title":"Absence of pharmacokinetic interactions between the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib and methotrexate","volume":"371","author":"Jones","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0048","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/00365513.2019.1706190","article-title":"Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial","volume":"80","author":"Odderskov","year":"2020","journal-title":"Scand J Clin Lab Investig"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpdd.280","article-title":"Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0050","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.1780370609","article-title":"Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis","volume":"37","author":"Seideman","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.xphs.2026.104348_bib0051","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/keg277","article-title":"Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone","volume":"42","author":"Fox","year":"2003","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00257235","article-title":"Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia","volume":"10","author":"Pinkerton","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0053","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00262278","article-title":"Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate","volume":"18","author":"Sonneveld","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0054","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0277-5379(87)90307-5","article-title":"Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate","volume":"23","author":"Lena","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cts.13125","article-title":"Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function","volume":"15","author":"Barreto","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0056","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0057","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1440-1681.1982.tb00800.x","article-title":"The protein binding and elimination of methotrexate after intravenous infusions in cancer patients","volume":"9","author":"Paxton","year":"1982","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"10.1016\/j.xphs.2026.104348_bib0058","first-page":"3487","article-title":"Effect of route of administration and effusions on methotrexate pharmacokinetics1","volume":"34","author":"Wan","year":"1974","journal-title":"Cancer Res"},{"key":"10.1016\/j.xphs.2026.104348_bib0059","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/B978-0-12-374970-3.00005-6","article-title":"Inferences for two populations","author":"Freund","year":"2010","journal-title":"Stat Methods"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0060","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/acs.molpharmaceut.3c01147","article-title":"Ontogeny of Human liver aldehyde oxidase: developmental changes and implications for drug metabolism","volume":"21","author":"Subash","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104348_bib0061","article-title":"Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling","author":"Hunt","year":"2023","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0062","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt.409","article-title":"Ontogeny of hepatic drug transporters as quantified by LC-MS\/MS proteomics","volume":"100","author":"Prasad","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0063","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0064","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/17460441.2024.2348157","article-title":"Another string to your bow: machine learning prediction of the pharmacokinetic properties of small molecules","volume":"19","author":"Bassani","year":"2024","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/dmd.113.053819","article-title":"Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype","volume":"42","author":"Prasad","year":"2014","journal-title":"Age Sex Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.xphs.2026.104348_bib0066","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11095-020-02964-z","article-title":"Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions","volume":"37","author":"Britz","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104348_bib0067","unstructured":"Probenecid PBPK model and conversion reference concentration v9- v11 PKsim. 2023."},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0068","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.102.034330","article-title":"Characterization of methotrexate transport and its drug interactions with human organic anion transporters","volume":"302","author":"Takeda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.xphs.2026.104348_bib0069","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1053\/gast.2001.24804","article-title":"LST-2, A human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers","volume":"120","author":"Abe","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.xphs.2026.104348_bib0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.xphs.2026.104348_bib0071","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1021\/jm030999b","article-title":"A physiological model for the estimation of the fraction dose absorbed in humans","volume":"47","author":"Willmann","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2026.104348_bib0072","series-title":"Abstracts of the Annual Meeting of the Population Approach Group in Europe: PAGE","article-title":"Simulating oral absorption with PK-Sim\u00ae methodology and application examples","author":"Willmann","year":"2006"},{"key":"10.1016\/j.xphs.2026.104348_bib0073","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00570494","article-title":"Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia","volume":"20","author":"Pearson","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2026.104348_bib0074","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1124\/dmd.122.000968","article-title":"Predicting in vivo target occupancy (TO) profiles via physiologically based pharmacokinetic\u2013TO modeling of Warfarin pharmacokinetics in blood: importance of low dose data and prediction of stereoselective target interactions","volume":"51","author":"Lee","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.xphs.2026.104348_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1208\/s12248-024-00979-7","article-title":"Exploring the impact of pharmacological target-mediated low plasma exposure in lead compound selection in drug discovery \u2013 a modeling approach","volume":"26","author":"Xu","year":"2024","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0076","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00558450","article-title":"Dose dependent methotrexate elimination following bolus intravenous injection","volume":"17","author":"Lawrence","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2026.104348_bib0077","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.123.001344","article-title":"A 20-year research overview: quantitative prediction of hepatic clearance using the in vitro-in vivo extrapolation approach based on physiologically based pharmacokinetic modeling and extended clearance concept","volume":"51","author":"Sugiyama","year":"2023","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0078","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cpt.176","article-title":"Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group","volume":"98","author":"Brouwer","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104348_bib0079","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejps.2018.08.042","article-title":"Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants","volume":"124","author":"van Groen","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10928-017-9559-4","article-title":"A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim","volume":"45","author":"Niederalt","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.xphs.2026.104348_bib0081","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11095-022-03211-3","article-title":"Consideration of fractional distribution parameter fd in the Chen and Gross method for tissue-to-plasma partition coefficients: comparison of several methods","volume":"39","author":"Jeong","year":"2022","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0082","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1208\/s12248-022-00732-y","article-title":"Determination of the number of tissue groups of kinetically distinct transit time in whole-body physiologically based pharmacokinetic (PBPK) models I: theoretical consideration of bottom-up approach of lumping tissues in whole-body PBPK","volume":"24","author":"Jeong","year":"2022","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0083","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1208\/s12248-022-00733-x","article-title":"Determination of the number of tissue groups of kinetically distinct transit time in whole-body physiologically based pharmacokinetic (PBPK) models II: practical application of tissue lumping theories for pharmacokinetics of various compounds","volume":"24","author":"Jeong","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104348_bib0084","unstructured":"ChemAxon. Chemicalize.com. 2022."},{"key":"10.1016\/j.xphs.2026.104348_bib0085","first-page":"1071","article-title":"Exploring QSAR - hydrophobic, electronic, and steric constants","author":"Hansch","year":"1995","journal-title":"Am Chem Soc"},{"key":"10.1016\/j.xphs.2026.104348_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112059","article-title":"Improvement of pharmacologically relevant properties of methotrexate by solid dispersion with pluronic F127","volume":"124","author":"Agafonov","year":"2021","journal-title":"Mater Sci Eng: C"},{"issue":"2","key":"10.1016\/j.xphs.2026.104348_bib0087","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","article-title":"General approach for the calculation of tissue to plasma partition coefficients","volume":"22","author":"Schmitt","year":"2008","journal-title":"Toxicol Vitro"},{"issue":"5","key":"10.1016\/j.xphs.2026.104348_bib0088","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02353860","article-title":"Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125","volume":"22","author":"Kawai","year":"1994","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104348_bib0089","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.106.110379","article-title":"Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2\/ABCC2- and MRP4\/ABCC4-mediated methotrexate transport","volume":"320","author":"El-Sheikh","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"10.1016\/j.xphs.2026.104348_bib0090","first-page":"7225","article-title":"Transport of methotrexate (MTX) and folates by multidrug resistance Protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport1","volume":"61","author":"Zeng","year":"2001","journal-title":"Cancer Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:31:58Z","timestamp":1788507118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001978"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104348","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A unified physiologically based pharmacokinetic model for low-to-high oral, subcutaneous, and intravenous dose of methotrexate in humans","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104348"}}